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Effect of Aflibercept on macular retinal layers and peripheral non perfusion in subjects
with Proliferative Diabetic retinopathy
Abstract:
Background: The relation between UWF fluorescein angiography (FA) and retinal nonperfusion were studied previously. The relationship between retinal thickness and retinal nonperfusion in subjects with diabetic retinopathy has not been studied using SD-OCT and UWF.
Thus, in this current study we used SD-OCT to visualize the individual layers of retina and to
evaluate whether the extent of non-perfusion is correlated with macular retinal layer thickness in
subjects with PDR with no diabetic macular edema.
Methods: In this prospective longitudinal multicenter, randomized study a total of 36 eyes of
thirty-six subjects were included in final analysis. Subjects with any history of anti-VEGF
therapy, steroid therapy, pan-retinal photocoagulation or vitreoretinal surgery, macular edema, or
SD-OCT determined central retinal thickness (CRT) of more than 320 μm in the study eye were
excluded. All subjects underwent ETDRS BCVA testing, slit lamp and indirect ophthalmoscopy
examination and diagnostic testing at all visits using Optos 200Tx (Optos plc, Dunfermline,
United Kingdom), Heidelberg Spectralis OCT (Heidelberg Engineering, Heidelberg, Germany)
with 9X image averaging. UWFA images were obtained and then transformed to stereographic
projection images using proprietary manufacturer software. Regions of non-perfusion were
identified and manually graded using Image J.
Results: The mean age of the subjects was 57 ± 13 years and 19 were female. The mean total
retinal thickness was significantly lower at month 12 when compared to baseline 258.47 ± 23.52
µm vs. 285.19 ± 23.62 µm (p <0.001). The thicknesses of NFL, GCL, IPL, ONL and EZ were
significantly thinned at month 12 when compared to baseline (p <0.05). Whereas OPL layer was
significantly thickened (p <0.05). No significant change was observed for INL and RPE at month
12 (p >0.05). For both the treatment arms, the mean total NPA at month 12 (280 ± 143 mm2)
increased, but not significantly (p=0.12) differ, when compared with baseline (242 ± 169 mm2).
Ischemic index (ISI, %), however, was significantly (p=0.009) increased at month 12 (34 ± 17)
when compared with baseline (27 ± 16).
Conclusion: The total NPA was significant and independently correlated with GCL and thinning
of inner retinal layers continues even after treatment. The thickness of multiple retinal sublayers
appears to decrease over time in eyes receiving intravitreal aflibercept for proliferative diabetic
retinopathy despite an absence of a change in peripheral non-perfusion. The underlying
pathophysiology for these reductions over time warrants further investigation.
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ABBREVIATIONS:
BCVA = Best-Corrected Visual Acuity;
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DR = Diabetic Retinopathy;
DME = Diabetic Macular Edema;
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FA = Fluorescein Angiography;
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NPA = Non-Perfusion Area;
SD-OCT = Spectral Domain Optical Coherence Tomography;
UWF = Ultra-Widefield;
VEGF = Vascular Endothelial Growth Factor.
RISE = Ranibizumab injection in subjects with clinically significant in macular edema
RIDE = Ranibizumab injection in subjects with diabetic macular edema
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Background:
Diabetic retinopathy (DR) is a microvascular complication that can lead to vision loss due to
increased vessel permeability, retinal ischemia and neovascularization in the working age
group.1,2 The most advanced stage of DR is proliferative diabetic retinopathy (PDR), which
develops as retinal ischemia, causing the existing vasculature to develop abnormal new vessels
(hypoxia).3 Left untreated, these hypoxic changes can cause vascular bleeding, vitreous
hemorrhage, traction, and retinal detachment4 secondary to neovascularization on the optic disc
(NVD) or neovascularization elsewhere (NVE), leading to vision loss.5 Pharmaceutical agents
that specifically inhibit Vascular Endothelial Growth factor (VEGF) including the FDAapproved agents aflibercept (Eylea, Regeneron) and ranibizumab (Lucentis, Genentech), as well
as the off-label us of repackaged bevacizumab (Avastin, Genentech) have revolutionized the
management of all forms of DR. Multiple prospective, randomized trials focusing on the
management of DME have demonstrated that anti-VEGF therapy can significantly blunt the
progression of non-proliferative DR (NPDR) to PDR. For example, PDR events were reduced in
the Ranibizumab injection in subjects with clinically significant in macular edema (RISE)/
Ranibizumab injection in subjects with diabetic macular edema (RIDE) phase 3 trials at 2 years
from approximately 34% with sham treatment to 11% with monthly ranibizumab treatment.6,7
The role of anti-VEGF pharmaceuticals in the management of DR may be much more important
than simply blunting progression to PDR and improving DR severity as assessed by color fundus
photography. VEGF blockade may be fundamentally impacting the underlying disease
pathophysiology of progressive retinal non-perfusion. Consistent with this, in Ranibizumab
injection in subjects with clinically significant in macular edema (RISE)/ Ranibizumab injection
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in subjects with diabetic macular edema RIDE, the development of angiographically-identified
NPA was significantly reduced with monthly VEGF blockade.8
Examination of the peripheral retina and retinal ischemic status may be a key factor in the
evaluation of PDR. Several ultra-wide field (UWF) imaging studies have demonstrated that
extensive and clinically important pathology may be present in the peripheral retina.9–12 Wessel
et al.11 reported finding 3.9 times more non-perfusion and 1.9 times more neovascularization
using Ultra Wide Field (UWF) than in traditional Early Treatment of Diabetic Retinopathy Study
(ETDRS) seven-field images. Unoki et al13 reported that areas of capillary nonperfusion
resulting from severe nonproliferative or proliferative diabetic retinopathy showed morphologic
changes in retinal structure.
A number of studies have been published on UWF fluorescein angiography (FA) and
retinal non-perfusion; but, to our knowledge, only a few of these studies showed any relationship
between retinal thickness and retinal non-perfusion in subjects with diabetic retinopathy.15 The
relationship between retinal layer thickness and peripheral non-perfusion in diabetic retinopathy
has not been studied using spectral-domain optical coherence tomography (SD-OCT) and UWF
FA. Thus, in this current study we used SD-OCT to visualize the individual layers of retina and
to evaluate whether the extent of non-perfusion is correlated with macular retinal layer thickness
in subjects with PDR with no diabetic macular edema and to evaluate the longitudinal changes in
individual retinal layers after anti VEGF treatment in PDR with no DME.
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Methods:
In this prospective longitudinal multicenter, randomized study (ClinicalTrials.gov Identifier:
NCT 02863354) 40 eyes of forty subjects were included. An Institutional Review Board
approval was obtained and is complied with the Declaration of Helsinki and the requirements of
the Health Insurance Portability and Accountability Act (HIPAA). All subjects signed the
HIPAA authorization, written informed consent for treatment and participation in the study was
obtained before enrollment. To be eligible for the study, patients had to be ≥ 18 years old, with
early treatment-naïve PDR secondary to DM (Type 1 or 2) in the study eye. Participants were
required to have ETDRS best corrected visual acuity (BCVA) of 19 (20/400 Snellen equivalent)
or more letters determined by protocol trial lens refraction at 4 meters, and with substantial nonperfusion (defined as greater than 20 disc areas) in the study eye were enrolled into the study.
Subjects with a previous history of anti-VEGF therapy, steroid therapy, pan-retinal
photocoagulation or vitreoretinal surgery and those with any history of macular edema, or SDOCT determined central retinal thickness (CRT) of more than 320 μm in the study eye were
excluded. All subjects underwent ETDRS BCVA testing, slit lamp and indirect ophthalmoscopy
examination and diagnostic testing at all visits using Optos 200Tx (Optos plc, Dunfermline,
United Kingdom), Heidelberg Spectralis OCT (Heidelberg Engineering, Heidelberg, Germany)
with a volume/cube acquisition protocol (20 x 20, 49 lines, 768 A-scans per line) with nine-times
image averaging.
Retinal image acquisition:
Study eyes were dilated using tropic amide 1% and phenylephrine 2.5%, and UWF pseudo color
images were captured after dilation using the Optos 200Tx centered on the fovea. After
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intravenous administration of fluorescein dye, UWF fluorescein angiography (FA) images were
obtained during the early (45 seconds), middle (2 minutes and 30 seconds), and late (5 minutes)
phases of the angiogram, and steered peripherally (nasally, temporally, superiorly, and inferiorly)
in all three phases.
UWF FA Image projection:
Uncorrected native images from the baseline visit were exported and sent to the Doheny Image
Reading Center (Doheny Eye Institute, Los Angeles, California) for grading. Images were then
transformed to stereographic projection images using proprietary software available from the
manufacturer. This projection technique was accomplished by ray tracing every pixel through a
combined optical model of the Optos 200Tx and a Navarro UWF model eye with an axial length
of 24 mm.8 This optical model represented the projection used by the Optos 200Tx scanning
laser ophthalmoscopy platform to create the 2-dimensional Optomap.
• Non-Perfusion Area Analysis:
Regions of non-perfusion were identified by the absence of retinal arterioles and capillaries with
hypo-fluorescence relative to the background. Two masked, trained, reading center-certified
UWF FA graders (S.B.V and M.G.N) independently analyzed the image according to
standardized reading center grading protocols at Doheny Image Reading Center.16 Graders were
allowed to adjust the contrast and brightness to optimize visualization of the areas of nonperfusion. Areas with an absence of 4th order and higher-order vessels was considered as
evidence of NPA (Figure 1 A). 1st, 2nd, and 3rd order vessels adjacent to non-perfusion areas were
included in the area measurements using a middle-phase FA frame. Using Image J version 1.49b
(US National Institutes of Health, Bethesda, MD), the graders manually delineated the peripheral
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extent of the visible retina and the borders of the non-perfusion area (NPA) (Figure 2); the
software then automatically calculated the number of pixels within the regions. The number of
pixels of capillary non-perfusion was calculated as a percentage of the total number of pixels of
NPA within the visible retina. The manually annotated regions were then exported as a binary
mask; these masks were later transformed into stereoscopic projection and their area was
automatically calculated in mm2 by summing the size of all pixels using software provided by
the manufacturer (Optos plc). Total non-perfusion area and macular non perfusion area (3mm
radius ring centered to the fovea) were generated at baseline and month 12 visits (Figure 1B).
Ischemic index was calculated as the ratio of NPA to the total visible retina.17 If there was a
difference in NPA > 20% between graders, the graders met in open adjudication to agree on a
single consensus result for each case. When differences smaller than this threshold were present,
the results of the two graders were averaged to yield a final result for subsequent correlative
analyses.
• SD- OCT Retinal Layer Thickness Analysis:
Uncorrected native images from all visits were exported and sent to the Doheny Image Reading
Center (Doheny Eye Institute, Los Angeles, California) for grading. Raw data from Heidelberg
Spectralis OCT was imported into the previously described and validated reading center custom
grading software (OCTOR).18 Then various retinal layers, i.e., vitreous top, nerve fiber layer
(NFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer
plexiform layer (OPL), outer nuclear layer (ONL), ellipsoid zone (EZ), retinal pigment
epithelium (RPE), choroid and total retina were segmented in each B-scan of the macular volume
and their thicknesses were measured (Figure 3).
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The space extending between the ILM-inner and NFL-outer is defined as nerve fiber
layer; NFL-outer to GCL- outer is defined as ganglion cell layer; the GCL-outer to IPL-outer is
defined as inner plexiform layer; IPL-outer to INL-outer is defined as inner nuclear layer; INLouter to OPL-outer is defined as outer plexiform layer; OPL-outer to ONL-outer is defined as
outer nuclear layer; EZ to RPE inner is defined as ellipsoid zone thickness; RPE-inner to RPEouter is retinal pigment epithelium, choroid-inner to choroid-outer is choroid and ILM- inner to
RPE-inner is defined as total retina. The automated segmentation was followed up with manual
correction for any segmentation errors in detail. Retinal thickness maps were generated for all 49
B-scans for all subjects.
Statistical analysis:
In final analysis, 36 eyes were included, as 4 eyes of four subjects were excluded from the study
due to missed follow-up (2 subjects) and diseased (2 subjects). Descriptive statistics were
analyzed for total study sample. The mean differences at baseline and month 12 visits were
calculated using paired sample t test. Similarly, the change analysis at month 12 visit between
cohorts were analyzed using paired sample t test. For baseline data, correlations between the
non-perfusion area (total and macular non perfusion area) and individual retinal layers thickness
was analyzed using bivariate Pearson correlations. And multivariate analysis was performed
using regression analysis. Statistical results were expressed as P values. A P value of less than
0.05 was considered statistically significant. All statistical analysis were performed using SPSS
18.0 statistical software (SPSS, Chicago, IL).
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Results:
A total of thirty-six eyes of 36 subjects with PDR were included in this study. The mean age was
57 ± 13 years and 19 were female. The mean total retinal thickness was significantly lower at
month 12 when compared to baseline 258.47 ± 23.52 µm vs. 285.19 ± 23.62 µm (p < 0.001). The
thicknesses of NFL, GCL, IPL, ONL and EZ were significantly thinned at month 12 when
compared to baseline (p < 0.05). Whereas OPL layer was significantly thickened at month 12
compared to baseline (p < 0.05). No significant change was observed for INL and RPE at month
12 (p >0.05). The individual retinal layers thickness measurements at baseline, month 12 and
change at month 12 were shown in table 1.
For the entire study sample, the mean total NPA at month 12 (280 ± 143 mm2) increased, but not
significantly (p = 0.12) differ, when compared with baseline (242 ± 169 mm2). Ischemic index
(ISI, %), however, was significantly (p=0.009) increased at month 12 (34 ± 17) when compared
with baseline (27 ± 16). Meanwhile, total area of neovascularization (NV), which was calculated
by combining neovascularization of the disc (NVD) and neovascularization elsewhere (NVE),
decreased dramatically from 20 mm2 to 1.02 mm2 (P = 0.004, As shown in Table 2).
Correlation Analysis between retinal layers and total NPA:
The relation between total NPA and the thickness of various retinal layers was studied using
univariate correlation analysis which showed a significant correlation between total NPA and
thickness of the NFL (r = -0.34, p = 0.03), GCL (r = -0.48, p = 0.002), IPL (r = -0.46, p = 0.003),
and INL (r = -0.31, p = 0.04). We also observed significant relation between total NPA and total
retinal thickness (r = -0.38; p= 0.01). Similar results were observed for macular non perfusion
also as shown in Table 3. The total NPA showed no significant correlation with the thickness of
the OPL, ONL, EZ, and RPE (p > 0.05). All parameters (NFL, GCL, IPL, and INL thicknesses)
15

which were significant on univariate analysis (p ≤ 0.05) were included in the multivariate
analysis. Only GCL thickness remained independently correlated with total NPA [R2 = 0.23, p =
0.002] and ischemic index [R2 = 0.12, p = 0.03].
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Discussion:
In the current study, we evaluated the effect of intravitreal aflibercept on individual retinal layers
thickness at macula and the total non-perfusion across the entire retina as determined by UWF
FA. The thickness of multiple retinal sublayers appears to decrease over time in eyes receiving
intravitreal aflibercept for PDR.
We have excluded subjects with any evidence of macular edema from study enrollment,
and thus confounding effect of exudation of the measurement of retinal sublayer thickness was
eliminated. The correlation of VEGF production with resultant macular edema and the extent of
retinal non-perfusion is well known.19 It has been studied in diseases like branch retinal vein
occlusion by Singer et al.20
Previous studies have described positive relation between capillary loss and macular
edema.21–23 In current study, we showed a significant reduction of inner retinal layers (NFL till
the OPL) thickness after anti VEGF treatment and also showed thinning of inner retina layers
with respect to the total non-perfusion area. Total (macular and peripheral) non perfusion area
was significantly correlated with inner retinal layers, more interestingly multivariate analysis
showed only GCL is independently correlated with total NPA. Rabiolo et al24 reported a
significant correlation between the ischemic index and area of FAZ measured at full thickness
and superficial layers and also showed primary involvement of inner retinal layers with respect
to disease severity. An OCT based study by Sim et al25 showing an inverse correlation between
the FAZ area and the RNFL thickness also confirmed the involvement of inner retinal layers, as
shown by various other studies.26–28 We observed significant thinning of retinal layers like NFL,
GCL, IPL, ONL and EZ at 1 year follow up and significant increase in thickness of OPL and
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RPE and also observed increase in total NPA, which indicates with respect to severity of NPA
inner retinal layers are effected at most.
This study highlights the association and early loss of inner retinal layers in eyes with
peripheral retinal capillary loss in eyes with PDR. We also observed a significant progressive
accumulation of non-perfusion through 1 year in the entire population. This indicates that the
NPA underlying DR is a progressive process that appears to be largely not reversible with
aflibercept treatment.
Notably, aflibercept treatment within RECOVERY did appear to have a biological impact
on NPA. The documentation of reduced NPA development with anti-VEGF dosing is consistent
with analyses of the RIDE/RISE dataset in which ranibizumab dosing slowed both development
and progression of NPA, compared to sham treatment.8 However, despite the presumably
valuable clinical impact of slowing NPA accumulation in RIDE/RISE data, NPA accumulation
was not halted and area of NPA did not appear to decrease in treated eyes across the population8,
consistent with the findings of RECOVERY.
It is noteworthy that treatment naïve PDR eyes with such dramatic NPA were adequately
controlled, without development of DME or progressive PDR or need for rescue PRP, through
aflibercept treatment. The Diabetic Retinopathy Clinical Research Network (DRCR.net) protocol
S employed 4-6 monthly ranibizumab loading doses for PDR management before anti-VEGF retreatments were individualized.29 Clinically, intravitreal anti-VEGF dosing can dramatically
decrease the extent of visible vascular abnormalities such as intra-retinal hemorrhages,
microaneurysms, intra-retinal microvascular abnormalities and venous beading, all considered
when quantifying a particular photography-based grade.
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At a deeper level NPA has proven to be a clinical marker with important prognostic
value. Specifically, in the face of consistent and intensive anti-VEGF treatment, some eyes will
nonetheless experience DR severity worsening. Through 3 years in RIDE/RISE study,
approximately 18%, or nearly 1 in 5 subjects, developed a PDR event despite monthly
ranibizumab dosing; in this context, the only statistically significant prognostic factor identified
for progression to a PDR event was the presence of baseline NPA.7 NPA has also been identified
as a significant prognostic indicator of progression to PDR among eyes with DME treated with
fluocinolone acetonide.30 The current work indicates that location of NPA may also be clinically
relevant. A statistically significant progression of NPA within the largest zone, 15 mm indicate
that retinal vasculature in the mid-periphery may be particularly sensitive to progressive vascular
damage.
Strengths of the current study are, this is the first study showing the effects of peripheral
retinal capillary loss on central retinal layer thickness till date with laborious manual
segmentation of all individual retinal layers. And another strength of the study was the use of
stereographically projected images for ischemic index calculation, to nullify the effect of
peripheral image distortion and magnification. This gives the precise measurements of the
ischemic index, as was shown by Tan et al19. Restrictions of this randomized trial include the
limited number of subjects and inherent challenges in measuring NPA from fluorescein
angiographic images.
In conclusion, the thickness of multiple retinal sublayers appears to decrease over time in
eyes receiving intravitreal aflibercept for proliferative diabetic retinopathy despite an absence of
a change in peripheral non-perfusion. The underlying pathophysiology for these reductions over
time warrants further investigation
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Figures and Legends:
Figure 1: Definition of Retinal Non-Perfusion

A. Non-perfusion Area (NPA) was defined as an absence of 4th-order (red) and higher-order
vessels. 1st-, 2nd-, and 3rd-order vessels were illustrated in blue, orange and yellow respectively.
The area with an absence of 4th-and-higher-order vessels (black solid arrow) was considered
non-perfused whereas the area identified with the white solid arrow was considered perfused due
to visible 4th-and-higher-order vessels. B. Concentric rings (centered on the fovea) were used to
measure areas of NPA: 3-mm area (red; 3-mm radius, excluding the fovea), 10-mm area (yellow;
3- to 10-mm radius), 15-mm area (blue; 10- to 15-mm radius).
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Figure 2: Summation of Areas of retinal non-perfusion

A. Non-perfusion Area (NPA) were delineated using Image J on ultra-widefield fluorescein
angiography image. B. Binarized images were used to calculate the NPA.
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Figure 3: UWF Images segmented and unsegmented UWF Images and SD-OCT B-scans.
Note total retinal thickening in the temporal region due to ischemia in the non-perfused area.

(A) Ultra-Wide Field (UWF) image, (B) Segmented UWF image, (C) Optical Coherence
tomography (OCT) image, (D) Segmented OCT image.
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Tables
Table 1: Thickness of retinal layers and choroid at baseline and month 12 visits
Layer thickness (µm)
Baseline
Month 12
Change at Month 12
N= 36 eyes
Mean ± SD (Range)
Mean ± SD (Range)
Mean ± SD (Range)
Nerve Fiber Layer
38.72 ± 7.39 ( 27.2 - 51.1 )
33 ± 5.08 ( 25.1 - 41.7 )
-2.74 ± 14.72 ( -20.7 - 41.7 )
Ganglion Cell Layer
41.6 ± 4.44 ( 33.6 - 48.8 )
34.75 ± 5.02 ( 22.6 - 41.5 )
-3.66 ± 11.97 ( -12.5 - 34.1 )
Inner Plexiform Layer
33.41 ± 3.11 ( 27.4 - 38.6 )
29.95 ± 3.43 ( 22.7 - 33.9 )
-0.9 ± 10.57 ( -7.5 - 33.4 )
Inner Nuclear Layer
28.12 ± 3.06 ( 22.3 - 34.6 )
27.01 ± 1.68 (23.7 - 29.4 )
1.06 ± 8.83 ( -7.1 - 29.3 )
Outer Plexiform Layer
32.15 ± 3.17 ( 25.1 - 35.7 )
31.14 ± 3.66 ( 23.9 - 36.3 )
1.47 ± 10.54 ( -5.6 - 35.9 )
Outer Nuclear Layer
57.59 ± 5.24 ( 48.8 - 65.3 )
51 ± 9.35 ( 33.2 - 62.7 )
-2.16 ± 18.66 ( -19.8 - 54.1 )
Ellipsoid Zone
46.66 ± 49.73 ( 20.6 - 158 )
23.77 ± 3.8 ( 19.1 - 29.1 )
-24.27 ± 66.18 (-240.7 - 19.1)
RPE
30.8 ± 1.28 ( 28.6 - 33 )
30.26 ± 5.58 ( 24.1 - 44.3 )
1.84 ± 13.26 ( -7.2 - 44.3 )
Choroid
259.22 ± 3.24 (205.2-318.2)
230.86 ± 20.33 (181 - 253.8)
-8.43 ± 87.57 (-94.9 - 245.1)
Total Retina Thickness 285.19 ± 23.62( 249.6 -324.6) 258.47 ± 23.52(209.1 - 277.1)
-4.78 ± 86.3 ( -52.9 - 277.1 )
SD-Standard Deviation; p-significance levels; statistically significant levels were in bold
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pvalue
0.005
<0.001
<0.001
0.1
<0.001
0.02
<0.001
0.14
0.04
<0.001

Table 2: Baseline and Month 12 Non Perfusion Area and Neovascularization data for total study eyes (N=
36 Eyes)
Baseline
Week 52
pMean ± SD (Range)
Mean ± SD (Range)
value
834 ± 131 (629 ─ 1212)
Total retinal area (mm2)
909 ± 185 (650 ─ 1213)
0.16
1.11 ± 4.73 (0 ─ 28.29)
Non perfusion in 3 mm (mm2)
2 ± 2 (1 ─ 4)
0.25
48.92 ± 52.46 (0.3 ─ 296.42)
Non perfusion in 10 mm (mm2)
32 ± 24 (1 ─ 95)
0.06
173.12 ± 109.61 (38.18 ─ 611.54)
Non perfusion in 15 mm (mm2)
128 ± 78 (6 ─ 323)
0.006
280.1 ± 142.99 (68.39 ─ 817.43)
Total Non perfusion area (mm2)
242 ± 169 (60 ─ 774)
0.12
34 ± 17 (8 ─ 100)
Ischemic Index (%)
27 ± 16 (6 ─ 67)
0.009
1.02 ± 2.88 (0 ─ 12.66)
Total NVE/NVD area (mm2)
20 ± 35 (1 ─ 188)
0.004
NVE- Neovascularization Elsewhere; NVD- Neovascularization of the Disc
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Table 3: Retinal Layers Thickness and Univariate Correlation Analysis
Layers

Thickness (µm)

Total
Capillary Non
Perfusion r[p]

Macular
Capillary Non
Perfusion r[p]

Ischemic Index r[p]

Nerve Fiber Layer
Ganglion Cell Layer
Inner Plexiform Layer
Inner Nuclear Layer
Outer Plexiform Layer
Outer Nuclear Layer
Ellipsoid Zone
RPE
Choroid
Total Retina Thickness

37 ± 6 (27 - 54)
41 ± 5 (24 - 50)
34 ± 4 (23 - 42)
29 ± 3 (20 - 36)
32 ± 3 (23 - 36)
60 ± 8 (46 - 81)
25 ± 3 (21 - 30)
31 ± 2 (27 - 34)
258 ± 50 (158 - 369)
286 ± 23 (233 - 344)

-0.34 [0.03]
-0.48 [0.002]
-0.46 [0.003]
-0.31 [0.04]
-0.29 [0.71]
0.01 [0.93]
-0.11 [0.48]
-0.11 [0.49]
0.05 [0.73]
-0.38 [0.01]

-0.26 [0.10]
-0.55 [<0.001]
-0.51 [0.001]
-0.51 [0.001]
-0.54 [<0.001]
0.12 [0.46]
-0.11 [0.49]
-0.04 [0.79]
-0.17 [0.27]
-0.42 [0.007]

-0.33 [0.03]
-0.30 [0.05]
-0.30 [0.06]
-0.16 [0.36]
-0.18 [0.27]
0.05 [0.72]
-0.18 [0.28]
-0.11 [0.51]
0.14 [0.40]
-0.27 [0.08]

RPE-Retinal Pigment epithelium; µm-micro-meter; r-correlation coefficient; p-Statistical Significance
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